Additional immunohistochemical markers, such as Rb lost and p53 mutant pattern in pancreatic NECs compared with loss of ATRX, DAXX, and menin in panNETs, can help in separating these two entities [8, 9] (III, B). The gene discussed is TP53; the disease is pancreatic endocrine carcinoma.